Funding

ParcelBio

United States · Biotech · Healthtech

Develops potent and durable mRNA medicines using the APEXm platform for autoimmune and oncology

Visit parcelbio.comFunding history

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
Seed$13MBreyer Capital — Role not disclosedGeneral Catalyst — Role not disclosedMetaplanet — Role not disclosedSurgePoint Capital — Role not disclosedY Combinator (YC) — Role not disclosedZAKA VC — Role not disclosed

Investors

Breyer CapitalSeedGeneral CatalystSeedMetaplanetSeedSurgePoint CapitalSeedY Combinator (YC)SeedZAKA VCSeed

Coverage

May 7, 2026ParcelBio · Seed

Similar companies

Guoke Brain-ComputerBeijing startup developing non-invasive wearable brain-computer interfaces that combine brain-signal detection, decoding and neural modulation.Undisclosed · Seed
Pathos AIClinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.$237M · Series E
Star TherapeuticsBiotechnology company discovering and developing antibody therapies for diseases with significant unmet need.$200M · Private financing
Sourcesparcelbio.com ↗